Gil Loewenthal

This study analyzes plasma proteomic changes in NSCLC patients on immunotherapy to identify biomarkers of treatment response and resistance.

The paper develops a model of indel dynamics incorporating border-induced selection and applies it to human intron length distribution to explain long neutral sequences.

This paper introduces a probabilistic model for indel evolution that distinguishes insertions from deletions, showing higher deletion rates and negative correlation with population size in empirical data.

This paper describes an in-vitro evolution platform for discovering DNA oligonucleotides with tumoricidal activity and selectivity, showing efficacy against chemotherapy-resistant tumors.